{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-024301","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.810453+00:00","generated_at":"2026-06-17T09:06:38.537355+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CorMedix reports Q4 2022 net loss $8.2M; FDA grants Type A meeting for DefenCath resubmission","bullets":["Q4 2022 net loss $8.2M ($0.20/shr) vs $7.8M loss in Q4 2021; full-year net loss $29.7M ($0.74/shr).","Cash and short-term investments $58.8M at Dec 31, 2022; $7.2M raised via ATM in Q1 2023.","FDA granted Type A meeting in mid-April to discuss DefenCath NDA resubmission; CMO corrective actions completed.","Agreement with Siegfried AG (Hameln, Germany) as backup CMO for DefenCath manufacturing.","Promoted Erin Mistry to EVP/Chief Commercial Officer and Dr. Tushar Mukherjee to SVP/Head of Technical Operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-024301","json":"https://secwatch.observer/filing/0001213900-23-024301.json","markdown":"https://secwatch.observer/filing/0001213900-23-024301.md","text":"https://secwatch.observer/filing/0001213900-23-024301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023024301/0001213900-23-024301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023024301/ea176049-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:06:38.537355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99171aa9b9dfe240a56a3a865a21c7a0ead0e42b","claim":"CorMedix Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income net loss of $8.2 million, or $0.20 per share, compared with a net loss of $7.8 million, or $0.20 per share, in the fourt, EPS $0.20 per share.","evidence_excerpt":"CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023024301/0001213900-23-024301-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Net income","value":"net loss of $8.2 million, or $0.20 per share, compared with a net loss of $7.8 million, or $0.20 per share, in the fourt"},{"label":"EPS","value":"$0.20 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}